Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
Nepal J Epidemiol ; 11(2): 1006-1022, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1314533

ABSTRACT

BACKGROUND: The objectives of the study were to identify the psychological impacts of lockdown on medical students due to COVID-19 and to discover the educational perplexities being faced by these students during the lockdown. METHODS: A cross-sectional study was conducted at Sir Seewoosagur Ramgoolam Medical College (SSRMC), Mauritius. Questions were designed after an extensive review of the literature, so as to ensure relevance to meet the objectives of the study. RESULTS: Out of 700 undergraduate medical students, 663 participated, which equates to a response rate of 95%. 348 (52.5 %) of the students were stationed in their hometown and the remaining 315 (47.5 %) were stationed in Mauritius. 464(70%) of the students suffered from the psychological impacts of lockdown whereas 634(95.6%) of students suffered from the educational impact thereof. Mauritian students suffered a greater educational impact aOR4.236[1.606-11.173]. Psychological impacts aOR 1.280 [0.917-1.789] and educational impacts aOR 2.464 [1.076-5.647] were more prevalent in hometown-based students. Students pursuing their clinical studies had aOR1.219 [ 0.531-2.798] a greater educational impact as compared to preclinical studies. CONCLUSION: Lockdown triggered both educational and psychological impacts on medical students. On a psychological basis it was proven that the lockdown induced a feeling of guilt and had a greater psychological impact in pre-clinical students. The COVID-19 situation was simultaneously indicated to be a motivator in the majority of students; however, juxtaposed to this was the fact that various students felt as if they couldn't study at the same level that they were accustomed to due to the uncertainty of the situation.

2.
Journal of Biomedical Sciences ; 7(1):18-27, 2020.
Article in English | Nepal Journals Online | ID: covidwho-926476

ABSTRACT

Background:The causative virus of COVID-19 has been named SARS-CoV-2. It is the seventh coronavirus that is pathogenic to humans and the third in the series of human pathogenic beta coronaviruses. Patient zero was identified to have contracted the virus in Wuhan, China. Shortly after the initial identification of the virus and its symptoms, multiple studies concluded that the virus originated from the “Wuhan seafood market”, a notorious market place for illegal wildlife trade based in Wuhan, a city in the Hubei region of the People’s Republic of China. Globally, as of 7:02 pm CEST, 29 May 2020, there have been 5704736 confirmed cases of COVID-19, including 357736 deaths, reported to the WHO. The transmission of COVID-19 is primarily by way of respiratory droplets, which can be developed via means of coughing or sneezing, hence spreading the disease from one person to another person. The research proposed indicates the possibility of bats as being the natural cistern of SARS-CoV-2, hence making COVID-19 a zoonotic disease. The most suspected intermediate host is the Malayan pangolin. SARS-CoV-2 is a single-stranded RNA virus that has an affinity for ACE2 receptors in humans, causing severe pathological symptoms. Symptoms like anorexia, dyspnea, fatigue, pyrexia, cough, headache, dizziness, nausea, productive sputum, abdominal pain, myalgia, sore throat, diarrhea, and vomiting. Vaccines that are currently in the clinical evaluation are the Adenovirus type 5 vector, mRNA-1273, Inactivated alum, ChAdOx, LNP-mRNA, DNA plasmid vaccine with electroporation and Inactivated vaccines. A Phase III randomized multicountry clinical trial comprising of 100 countries known as “Solidarity” (ISRCTN83971151) has been initiated by the WHO to achieve the unified goal of producing an adequate treatment for COVID-19. The present Solidarity trial focuses on the following drugs: Remdesivir, Lopinavir/Ritonavir with or without interferon beta-1a, Chloroquine, or hydroxychloroquine. Conclusion: It is invariably essential to promote research in this field of study and find an appropriate solution to the virus to allow individuals worldwide to lead a secure and healthy life.

3.
Nepal J Epidemiol ; 10(2): 845-855, 2020 Jun.
Article in English | MEDLINE | ID: covidwho-740486

ABSTRACT

This narrative review of the literature aims to assess the impact of COVID-19 on the younger age group in terms of the Global mortality of COVID-19 in comparison to Nepal. An extensive literature survey of English literature was conducted using Pubmed, Medline, Google Scholar, Embase, WHO Nepal Situation Updates on COVID-19, Situation update report, Ministry of Health and Population-Nepal from January 25, 2020 to June 20, 2020. According to the Ministry of Health and population of The Government of Nepal, as of June 20, 2020, out of a total of 8,605 laboratory confirmed cases reported to date, the pattern shows that most of the cases fell into the cohort of 21-30 years (37.72%), followed by 11-20 years (24.35 %), 31-40 years (21.97%) and 41-50 years (9.2%). To date Nepal has recorded a total of twenty-two deaths. At first evaluation these figures may not strike one as alarming, but on further investigation it is noted that the mean age is 42. 32 ± 19.632 SD years, and out of which male patients accounted for 77.3% and female accounted for 22.7%. The current situation of COVID-19 and how it develops in Nepal should be closely monitored and could be of international concern as it may be the early indicator of a changing pattern in COVID-19 infections. Nepal may therefore act as a global watch dog, due to the fact that the world could very possibly expose the younger age group under the notion that they are more resilient to the virus, when in reality that notion may be changing. This trend must be monitored and further investigated in order to establish the risk of the events unfolding in Nepal.

SELECTION OF CITATIONS
SEARCH DETAIL